Advertisement
Advertisement

FATE

FATE logo

Fate Therapeutics, Inc.

3.08
USD
Sponsored
+0.08
+2.84%
Jul 07, 11:31 UTC -4
Open

FATE Earnings Reports

Positive Surprise Ratio

FATE beat 24 of 42 last estimates.

57%

Next Report

Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.39M
/
-$0.27
Implied change from Q1 26 (Revenue/ EPS)
+7.25%
/
+3.85%
Implied change from Q2 25 (Revenue/ EPS)
-26.95%
/
-3.57%

Fate Therapeutics, Inc. earnings per share and revenue

On May 13, 2026, FATE reported earnings of -0.26 USD per share (EPS) for Q1 26, beating the estimate of -0.28 USD, resulting in a 8.96% surprise. Revenue reached 1.30 million, compared to an expected 1.16 million, with a 11.81% difference. The market reacted with a -5.11% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 1.39 million USD, implying an increase of 3.85% EPS, and increase of 7.25% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Replimune Group, Inc.
Report Date
Jun 29, 2026 For Q4 26
Estimate
-$0.72
Actual
-$0.76
Surprise
-4.52%
logo
Beyond Air, Inc. Common Stock
Report Date
Jun 26, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.63
Surprise
-9.00%
FAQ
For Q1 2026, Fate Therapeutics, Inc. reported EPS of -$0.26, beating estimates by 8.96%, and revenue of $1.30M, 11.81% above expectations.
The stock price moved down -5.11%, changed from $2.25 before the earnings release to $2.13 the day after.
The next earning report is scheduled for Aug 05, 2026.
Based on 13 analysts, Fate Therapeutics, Inc. is expected to report EPS of -$0.27 and revenue of $1.39M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement